# US 2025/0059517 A1 · Media and methods for making and maintaining porcine pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059517 A1
- Document ID: US20250059517A1
- Status: Published application
- Kind: A1
- Application number: 18/807,650
- Filed: 2024-08-16
- Published: 2025-02-20
- Earliest claimed: 2023-08-18
- Assignees: Recombinetics, Inc.
- Applicants: Recombinetics, Inc.
- Inventors: Abigail Sproull; Ohad Gafni
- Web page: https://patentgrep.com/patent/US20250059517A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0611: {Primordial germ cells, e.g. embryonic germ cells [EG]}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2500/38: Vitamins
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/48: Regulators of apoptosis
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/605: Nanog
- C12N 2501/606: c-Myc
- C12N 2501/608: Lin28
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to methods for making porcine pluripotent stem cells. The present disclosure also relates to methods for gene-editing porcine pluripotent stem cells, generating animals from porcine pluripotent stem cells, and maintaining porcine pluripotent stem cells in culture over many passages. The present disclosure further relates to methods for making porcine induced pluripotent stem cells.

## Claims

### Claim 1

A method for making porcine pluripotent stem cells, the method comprising:
a) obtaining porcine cells;
b) culturing the porcine cells with porcine stem cell media, wherein the porcine stem cell media comprises one or more reagents selected from the group consisting of: a basal media, an L-glutamine source, a cell growth supplement, an antibiotic, a media stabilizer, an FGF protein, a SMAD regulator, an inhibitor of Lck, an inhibitor of Src, an inhibitor of Sik, a Wnt activator, a STAT3 activator, an antioxidant, ascorbic acid, and an inhibitor of apoptosis, thereby generating the porcine pluripotent stem cells.

### Claim at position 2

2-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the SMAD regulator comprises activin A.

### Claim 9 (depends on 1)

The method of claim 1, wherein the Wnt activator comprises CHIR99021.

### Claim 10 (depends on 1)

The method of claim 1, wherein the STAT3 activator is human leukemia inhibitory factor (LIF).

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the inhibitor of apoptosis comprises SP600125.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the porcine pluripotent stem cells maintain pluripotency over at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 or more passages.

### Claim 15 (depends on 1)

The method of claim 1, wherein the porcine cells comprise somatic cells.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The method of claim 15, wherein the porcine somatic cells are transfected with one or more reprogramming factors.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more reprogramming factors are encoded by one or more episomes.

### Claim 19 (depends on 17)

The method of claim 17, wherein the one or more reprogramming factors comprise one or more genes selected from the group consisting of: OCT3/4, SOX2, KLF4, C-MYC, LIN28, and NANOG.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the porcine cells comprise germ cells, and wherein the germ cells are combined via IVF to produce an embryo.

### Claim 22 (depends on 21)

The method of claim 21, wherein the embryo is transferred to porcine stem cell media between days 1 and 12 post-fertilization.

### Claim 23 (depends on 1)

The method of claim 1, wherein the porcine cells comprise cells obtained from non-IVF derived embryos.

### Claim 24 (depends on 1)

The method of claim 1, further comprising selecting morphologically stem cell-like colonies from the porcine stem cell media.

### Claim at position 20

25-27. (canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein the porcine pluripotent stem cells are gene-edited.

### Claim 29 (depends on 28)

The method of claim 28, wherein the porcine pluripotent stem cells are gene-edited via a CRISPR/Cas9 system, a CRISPR system, a TALEN system, a base editing system, a CRISPR/Cas9-derived RNA-guided engineered nuclease (RGEN) system, a zinc finger nuclease system, a prime editing system, or a variant thereof.

### Claim 30 (depends on 28)

The method of claim 28, wherein the porcine pluripotent stem cells are gene-edited at one or more target loci.

### Claim 31 (depends on 30)

The method of claim 30, wherein the gene-editing occurs at the one or more target loci simultaneously.

### Claim 32 (depends on 31)

The method of claim 31, wherein one, two, three, four, five, six, seven, eight, nine, or ten targe loci are edited simultaneously.

### Claim 33 (depends on 30)

The method of claim 30, wherein the gene-editing occurs at one or more target loci in series.

### Claim 34 (depends on 33)

The method of claim 33, wherein one, two, three, four, five, six, seven, eight, nine, or ten target loci are edited in series.

### Claim at position 28

35-51. (canceled)

### Claim 52 (depends on 1)

A stem cell line produced by the method of claim 1.
